Verona Pharma sees stock jump as COPD drug returns positive results


A Raleigh drugmaker hit its targets in a clinical trial for its lung disease treatment, putting the company on a potential path to obtaining approval from regulators.

Previous Accounting recruits are a hot commodity for Buffalo's public firms
Next Tech giant Intel invests in digital health firm BioFourmis' $320M Series D